Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia Therapeutics has announced early-stage clinical data suggesting that its investigational gene editing treatment may stabilise or improve outcomes for…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
-
-
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
-
Exact Sciences showcases early cancer detection test data at AACR meeting
Exact Sciences has unveiled new findings from a case-control study demonstrating the potential of its advanced multi-biomarker class approach to…
-
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Adaptimmune’s pivotal Phase II trial of its investigational T cell therapy lete-cel has met its primary endpoint, with the company…
-
Putting the DACH region on the map for clinical trials
Amid tightening EU regulations, a growing emphasis on digitalisation and artificial intelligence (AI), and complex questions around ethics, the viability…
-
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients with relapsed…
-
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its…
-
Boston Scientific resumes enrolment in pulsed field ablation trial
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a…
-
Cofactor’s cancer biomarker test outshines standard ICI predictive tests
Cofactor Genomics has showcased positive data highlighting that its clinical biomarker assay OncoPrism-HNSCC could guide doctors in choosing more effective…
-
Vidac secures funding to advance skin cancer trials of novel ointment
Vidac Pharma has secured €600,000 ($645,651) in additional funding to support the clinical development of its two lead cancer candidates. …